Holocene Advisors LP reduced its holdings in GSK plc (NYSE:GSK - Free Report) by 98.9% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 65,301 shares of the pharmaceutical company's stock after selling 5,624,394 shares during the quarter. Holocene Advisors LP's holdings in GSK were worth $2,670,000 at the end of the most recent quarter.
A number of other institutional investors have also recently modified their holdings of GSK. EverSource Wealth Advisors LLC lifted its holdings in GSK by 9.4% in the second quarter. EverSource Wealth Advisors LLC now owns 3,542 shares of the pharmaceutical company's stock valued at $137,000 after acquiring an additional 303 shares during the period. Mesirow Financial Investment Management Inc. boosted its holdings in GSK by 2.0% during the third quarter. Mesirow Financial Investment Management Inc. now owns 16,693 shares of the pharmaceutical company's stock worth $682,000 after buying an additional 323 shares in the last quarter. International Assets Investment Management LLC boosted its holdings in GSK by 6.3% during the second quarter. International Assets Investment Management LLC now owns 5,535 shares of the pharmaceutical company's stock worth $213,000 after buying an additional 327 shares in the last quarter. Investment Partners Asset Management Inc. increased its holdings in GSK by 2.3% in the third quarter. Investment Partners Asset Management Inc. now owns 15,559 shares of the pharmaceutical company's stock valued at $636,000 after buying an additional 344 shares in the last quarter. Finally, Chapin Davis Inc. lifted its position in shares of GSK by 2.5% during the 2nd quarter. Chapin Davis Inc. now owns 14,591 shares of the pharmaceutical company's stock valued at $562,000 after acquiring an additional 360 shares during the period. 15.74% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
GSK has been the topic of a number of research reports. Deutsche Bank Aktiengesellschaft cut GSK from a "buy" rating to a "hold" rating in a report on Friday, November 15th. Jefferies Financial Group lowered GSK from a "buy" rating to a "hold" rating and lowered their target price for the company from $53.00 to $39.50 in a report on Tuesday, November 12th. Barclays raised GSK to a "hold" rating in a research note on Tuesday, August 27th. StockNews.com cut shares of GSK from a "strong-buy" rating to a "buy" rating in a research note on Wednesday. Finally, Guggenheim downgraded shares of GSK from a "buy" rating to a "neutral" rating in a report on Thursday, October 31st. Seven equities research analysts have rated the stock with a hold rating, one has given a buy rating and three have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $43.25.
Check Out Our Latest Stock Report on GSK
Insider Transactions at GSK
In other news, major shareholder Plc Gsk purchased 2,791,930 shares of the stock in a transaction on Friday, September 27th. The stock was purchased at an average price of $8.00 per share, with a total value of $22,335,440.00. Following the completion of the transaction, the insider now owns 16,775,691 shares in the company, valued at approximately $134,205,528. The trade was a 19.97 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 10.00% of the company's stock.
GSK Trading Up 0.1 %
GSK stock traded up $0.04 during trading on Friday, hitting $34.57. The company's stock had a trading volume of 3,702,721 shares, compared to its average volume of 4,148,124. The stock's fifty day moving average is $36.78 and its 200 day moving average is $39.71. GSK plc has a 1-year low of $32.83 and a 1-year high of $45.92. The stock has a market capitalization of $71.65 billion, a price-to-earnings ratio of 22.45, a P/E/G ratio of 1.33 and a beta of 0.64. The company has a debt-to-equity ratio of 0.98, a quick ratio of 0.53 and a current ratio of 0.81.
GSK Increases Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, January 9th. Stockholders of record on Friday, November 15th will be paid a dividend of $0.3928 per share. The ex-dividend date of this dividend is Friday, November 15th. This represents a $1.57 dividend on an annualized basis and a dividend yield of 4.55%. This is an increase from GSK's previous quarterly dividend of $0.38. GSK's dividend payout ratio is currently 99.35%.
About GSK
(
Free Report)
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.
Further Reading
Before you consider GSK, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GSK wasn't on the list.
While GSK currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
